Prescribing information



ENERZAIR BREEZHALER is indicated as a maintenance treatment for asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a high dose of an inhaled corticosteroid, who experienced one or more asthma exacerbations in the previous year.1


  1. ENERZAIR BREEZHALER Summary of Product Characteristics.


Rate this content: 
Average: 3.7 (3 votes)
UK | February 2021 | 103399

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at